---------- CBD ----------

14 Phase I Selections from the 08.1 Solicitation

(In Topic Number Order)
LYNNTECH, INC.
7610 Eastmark Drive
College Station, TX 77840
Phone:
PI:
Topic#:
(979) 693-0017
Dr. Gareth Hughes
CBD 08-101      Awarded: 4/18/2008
Title:Sequential Isoelectric Point Separation of Proteins Using Non-Gel, Microfluidic System
Abstract:The measurement of biochemical changes within the human body can provide a means to monitor a person’s physiological health. Many of the biochemicals that provide a snapshot of a person’s health are proteins. The challenge with measuring proteins is the existence of approximately ten orders of magnitude difference in concentration between the most abundant proteins in blood and those typically used to determine disease and physiological state. This proposed effort aims to develop a modular mass spectrometer for proteome profiling of readily available biological fluids comprising of user-configurable components for applications ranging from field-deployable pathogenic detection to customizable assays for biomedical diagnostics. The specific innovation is in the fabrication and integration of discrete microscale subsystems, including microfluidic chips for sample processing and miniature mass analyzers for spectroscopic analysis. The small form factor of all components enables the manufacture of compact mass spectrometers that will eventually reside in domestic to far-forward military medical facilities, clinics, doctor’s offices, or even nearby the patient in the hospital setting. The compact form factor will also enable the development of systems for far-forward deployment capable of on-site detection and monitoring of biological warfare agents / toxins.

PHYSICAL OPTICS CORP.
Photonic Systems Division 20600 Gramercy Place, Bldg 100
Torrance, CA 90501
Phone:
PI:
Topic#:
(310) 320-3088
Dr. Gregory Zeltser
CBD 08-101      Awarded: 4/18/2008
Title:Combined Dielectrophoretic Microfluidic System
Abstract:To address the U.S. Army CBD need for a high resolution system whereby proteins present in a complex mixture can be rapidly and reproducibly separated, Physical Optics Corporation (POC) proposes to develop a new Combined Dielectrophoretic Microfluidic (CDM) System based on the integration of electrodeless dielectrophoresis and dynamic isoelectric focusing techniques, used to carry out two-dimensional protein separation inside a microfluidic chip. The CDM system will be composed of a microfluidic chip, AC and DC power supplies, miniature syringe pump, readout unit, and computer. The CDM system will rapidly (7-8 min.), and with high resolution and reproducibility, separate proteins from a complex mixture, such as human cell homogenate. The CDM system will be an inexpensive, portable, and easy to use automated instrument. In Phase I, POC will demonstrate the feasibility of the CDM device by fabricating a prototype, and demonstrating its capability with all the individual proteins from a fairly simple mixture, in a rapid (<10 min.) and reproducible manner. In Phase II, CDM will rapidly (<10 min.) separate biologically relevant proteins in the molecular weight range of 16-200 Kd, and pI range of 3-12, from a complex mixture, such as human cell homogenate, in a reproducible manner.

AERIUS PHOTONICS, LLC.
4160 Market St., Suite 6
Ventura, CA 93003
Phone:
PI:
Topic#:
(805) 642-4645
Dr. Michael
CBD 08-102      Awarded: 5/30/2008
Title:Handheld IR Raman Spectroscopy for Rapid Chemical Identification
Abstract:Aerius Photonics and partner Ahura Scientific, propose to develop a handheld system, based on Ahura’s successful FirstDefender Raman system, that employs an excitation laser emitting at 980 nm and a low noise InGaAs array based on Aerius’ high performance InGaAs technology. This system will substantially reduce the fluorescence present in CCD-based systems, and unmask otherwise obscured spectra. The combination promises to establish a new standard for identifying low concentrations of chemicals using a compact, easy-to-use system. At the end of a successful Phase II, we would deliver a prototype unit having a footprint similar to the FirstDefender that is capable of identifying chemicals within seconds, and ready to be put into use very quickly. In Phase I of this program, we plan to build a breadboard version of the system that employs a 980 nm laser, a probe, a miniature spectrometer, and an InGaAs array.

REAL-TIME ANALYZERS
362 Industrial Park Road Suite #8
Middletown, CT 06457
Phone:
PI:
Topic#:
(860) 635-9800
Dr. Stuart
CBD 08-102      Awarded: 6/18/2008
Title:Hand-Held Raman Analyzer for Chemical Identification
Abstract:The overall goal of this proposed program (through Phase III) is to build a hand-held Raman analyzer that can perform non-contact identification of chemicals in the field. This will be accomplished by modifying a commercially available FT-Raman analyzer to employ 976 or 1064 nm laser excitation. Feasibility will be demonstrated in Phase I by comparing the ability of three Raman systems using laser excitation at 785, 976, and 1064 nm to measure some 50 chemicals in terms of fluorescence and thermal emission minimization, and identification of unknowns using spectral matching algorithms. During Phase II an ~ 10 pound hand-held Raman analyzer will be designed and built that includes a comprehensive spectral library of actual chemical warfare agents, explosives, and toxic industrial chemicals; and employs a Personnel Digital Assistant for analyzer control that includes spectral acquisition and spectral matching with statistics to allow chemical identification in real-time (< 5 minutes). The analyzer will employ a simple to operate user- interface, and will be delivered at the end of the program.

AGAVE BIOSYSTEMS, INC.
P.O. Box 80010
Austin, TX 78708
Phone:
PI:
Topic#:
(512) 656-6200
Mr. Noe Salazar
CBD 08-103      Awarded: 5/1/2008
Title:Collective Protection for Military Working Dogs
Abstract:Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs. The overall operational weight of the enclosure would also be a function of its power requirements which in turn is a function of its operating mode. Therefore, Agave BioSystems, in collaboration with Gentex Corporation and Dr. Joseph Wakshlag of the Cornell College of Veterinary Medicine, proposes to design and develop protective enclosures for military working dogs that meet these parameters. In the Phase I, this team will define the canine physiological and psychological parameters of importance to enclosure design; develop multiple designs to allow consideration for both powered and non-powered enclosures as well as active and passive materials; and demonstrate proof of concept for the protective capacity and long-term kenneling suitability of the designs.

TECHNICAL PRODUCTS, INC.
31 Willow Road
Ayer, MA 01432
Phone:
PI:
Topic#:
(978) 772-4980
Mr. Paul Chambers
CBD 08-103      Awarded: 5/5/2008
Title:Collective Protection for Military Working Dogs
Abstract:Doctrine for employment of canines in a CBRN environment has evolved into a Collective Protection approach. Providing COLPRO has several very significant implications for Canine kennels and shelters: „X The outer surface of the structure must be CB agent impervious „X The outer surface of the structure must resist effects of the decontamination process „X The system must provide the animal a supply of filtered air and provide for the discharge of exhaled air „X The system must manage the thermal environment and additional loading generated by the encapsulated canine Because of the potential for an extended dwell time within the COLPRO structure we have to add another set of requirements to the system ¡V management of the ¡¥hotel¡¦ functions: „X ¡¥atmospheric¡¦ humidity within the structure „X the animal¡¦s bodily waste „X noise from air supply and thermal management devices, etc. „X light levels within and visibility from outside the structure „X access to the animal by the handler We must also apply the limitations of low/no power requirements, low bulk for shipping and having a system which has broad or ideally universal applicability ¡V not just as a COLPRO device. Development of such a shelter is the subject of this proposal.

LOS GATOS RESEARCH
67 East Evelyn Ave. Suite 3
Mountain View, CA 94041
Phone:
PI:
Topic#:
(650) 965-7772
Dr. Douglas Baer
CBD 08-104      Awarded: 5/6/2008
Title:Dynamic Multicomponent Optical Analyzer for Chemical Weapon (CW) Exposure Studies
Abstract:In this SBIR Phase I effort, Los Gatos Research (LGR) proposes to design, develop and test a novel laser-based gas analyzer optimized for chemical weapon exposure studies based on cavity enhanced absorption in the mid-infrared spectral region. This analyzer will provide sensitive and accurate quantification of several chemical weapons through real-time measurements of high-resolution absorption spectra recorded in the mid- infrared. The instrument will employ Off-Axis ICOS, an extraordinarily rugged and commercially-proven cavity enhanced laser absorption technique that uses an optical cavity as absorption cell for significantly improved sensitivity, and mid-infrared lasers for high specificity and low false positives. The SBIR instrument will be the first system capable of providing rapid quantification of chemical agents and enable improved understanding of the dose-response characteristics of the subject in real time.

SCIENCE & ENGINEERING SERVICES, INC.
6992 Columbia Gateway Drive Suite 200
Columbia, MD 21046
Phone:
PI:
Topic#:
(443) 539-1731
Dr. Coorg R. Prasad
CBD 08-104      Awarded: 5/8/2008
Title:Dynamic Multicomponent Optical Analyzer for Chemical Weapon (CW) Exposure Studies
Abstract:We propose to build a compact laser photoacoustic spectrometric (LPAS) sensor for continuous, real-time broadband analysis of multiple chemical components, and perform field tests to qualify it for dynamic monitoring of chemical warfare agents (CWA). Our sensor will be based on our laboratory LPAS instrument (at technology readiness level TRL-4) that has already demonstrated successful multicomponent chemical detection with CWA1, toxic chemicals and explosives2. It utilizes a tunable infrared laser (CO2 or quantum cascade), a high sensitivity photoacoustic cell with an air sampler and an efficient algorithm to rapidly complete high sensitivity, selective multicomponent measurements in under a minute. In Phase I we will carry out extensive laboratory and preliminary field site tests of LPAS with simuants, and a comprehensive analysis of the sensor performance using a model to determine the LOD and ROC curves for the sensor and establish its feasibility. A rugged and portable prototype sensor (TRL-5) will be built in Phase II. It will be field tested with actual toxic agents in DoD test sites to qualify (TRL-6) and characterize the sensor.

SPECTRAL SCIENCES, INC.
4 Fourth Avenue
Burlington, MA 01803
Phone:
PI:
Topic#:
(781) 273-4770
Dr. Pajo Vujkovic-
CBD 08-104      Awarded: 4/28/2008
Title:Dynamic Multicomponent Optical Analyzer for Chemical Weapon (CW) Exposure Studies
Abstract:Spectral Sciences Inc. proposes to develop a prototype sensor for real-time trace-level analysis of complex multicomponent gas mixtures, specifically those containing Chemical Weapon (CW) agents and interferents. The instrument is based on high power quantum cascade lasers and photocoustic spectroscopy detection. Advanced detection algorithms take advantage of wide spectral coverage to provide high sensitivity with low occurrence of false positives. The laser source features digitally controlled fast wavelength tuning and wavelength modulation. An integrated-optics acoustic transducer provides noise-cancelling gas absorption signal acquisition. In Phase I and Phase I Option tasks, the digitally tunable and lockable laser source will be demonstrated, followed by the delivery of a laboratory prototype by the end of Phase II.

BIOPROTECTION SYSTEMS CORP.
2901 South Loop Drive Suite 3360
Ames, IA 50010
Phone:
PI:
Topic#:
(515) 296-3944
Dr. Ramon Flick
CBD 08-105      Awarded: 5/5/2008
Title:Multiple Indication Adjuvants
Abstract:The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant potency of the alphaGal Adjuvant Technology. This technology is based on the innate naturally acquired human immune response to galactose alpha(1,3)galactose alpha(1,4)N-acetylglucosamine (alphaGal) epitopes. In Phase I we will illustrate the broad application of the alphaGal Adjuvant Technology to antiviral vaccines by demonstrating that alphaGal-modification significantly enhances and modulates the immune response to select vaccines in a mouse model. In the Phase I Option, the optimized adjuvant conditions eliciting the best immune response to the different tested antiviral vaccines, based upon the mouse model immunological data, will be utilized in limited lethal challenge efficacy experiments to be conducted with wild-type virus under Biosafety Level (BSL)-4 conditions in the mouse model. Significant efficacy will lead to a Phase II proposal and further studies involving adjuvant efficacy in small rodents and non-human primates.

LUNA INNOVATIONS, INC.
1 Riverside Circle Suite 400
Roanoke, VA 24016
Phone:
PI:
Topic#:
(540) 769-8400
Dr. Krista Niece
CBD 08-107      Awarded: 5/8/2008
Title:Camouflaged liposome construct for efficient drug delivery across the blood-brain barrier
Abstract:A major obstacle to non-invasive treatment of brain injury and disease is the blood-brain barrier (BBB), which prevents many intravenously injected therapeutics from being taken into the brain. In this program, Luna Innovations and Virginia Tech propose to develop a novel liposome-based delivery system capable of delivering any of a variety of neuroprotective agents of use against organophosphate-based nerve agents. This novel system combines a recently developed “Trojan horse” peptide capable of ferrying the construct across the BBB with liposome technology previously developed at Luna that can be adapted to achieve drug delivery over a specified time frame. The proposed system also has neural specificity, targeting the tissues that are most affected by nerve agents. During Phase I, the Luna team will synthesize and assemble the system components, demonstrate encapsulation of assorted neuroprotective agents, and perform preliminary in vivo and in vitro testing of system efficacy.

LYNNTECH, INC.
7610 Eastmark Drive
College Station, TX 77840
Phone:
PI:
Topic#:
(979) 693-0017
Dr. Sriram Shankar
CBD 08-107      Awarded: 5/9/2008
Title:Blood Brain Barrier (BBB) Permeable Encapsulating Agents for Effective Delivery of CNS-active Agents
Abstract:Drug transport in the central nervous system is highly regulated by the Blood-Brain Barrier (BBB). Most medicines, including many for treating cancer, Alzheimer’s, and stroke, do not meet essential criteria, such as lipophilicity and low molecular weight, required for appreciable transport into the brain. However, endogenous peptides, such as insulin or transferrin, and certain monoclonal antibodies, undergo receptor-mediated transport (RMT) across the BBB in vivo after binding to specific receptors or transporters localized within brain capillary endothelial cells (BCEC). Brain-delivery of brain-impermeable therapeutics can be accomplished by attaching them as payloads to these macromolecules. BBB transport of large molecule pharmaceutical payloads – including recombinant proteins, other antibodies, RNA interference drugs, and non-viral gene medicines – has been mediated in this fashion. Novel liposomal and polymer encapsulation methods have made it more facile to transport a large number of such molecules, attached as a single payload to a receptor-targeting mAb, across the BBB. In Phase I of this project, Lynntech, in collaboration with Dr. Abbott at Texas A&M Univ., will evaluate a suite of novel platforms for payload encapsulation and demonstrate their effective receptor-mediated transport and delivery in the brain.

ACCACIA INTERNATIONAL, INC.
One Tech Plaza 2113 Wells Branch Parkway, Sui
Austin, TX 78728
Phone:
PI:
Topic#:
(512) 617-3387
Mrs. Jean Bishop
CBD 08-108      Awarded: 5/28/2008
Title:Oligonucleotide Enzyme Surrogate (OnES)
Abstract:Historically organophosphorus compounds such as insecticides and nerve agents have been susceptible to decomposition by proteinaceous enzymes. Organophosphate hydrolases (OPH) represent a practical method to deactivate such compounds peripherally and on surfaces. However, when such organophosphates are ingested, the use of proteinaceous enzymes such as OPH can be problematic because of their tendency to produce an immune response. In order to avoid this issue, Accacia International will manipulate DNA oligonucleotides using a novel and innovative selection method. DNA aptamers will be selected through the Systematic Evolution of Ligands by EXponential enrichment (SELEX) method to accomplish the task of creating an enzyme surrogate.

AGAVE BIOSYSTEMS, INC.
P.O. Box 80010
Austin, TX 78708
Phone:
PI:
Topic#:
(607) 272-0002
Dr. Janet Huie
CBD 08-108      Awarded: 5/28/2008
Title:Ribozymes for In Vivo Degradation of G-Nerve Agents
Abstract:Given the possibility to administer prophylactic doses of protein bioscavengers inactivating OP nerve agents before they reach their acetylcholinesterase target, much attention has been given to proteins such as human butyrylcholinesterase and paraoxonase I. As small nucleic acid catalysts can exhibit triphosphoesterase activities, the identification of new molecules active against nerve agents would constitute a significant breakthrough for the development of a biopharmaceutical approach against OP agents, with rapid optimization of catalytic rate, stability, large-scale production, storage and formulation. In this Phase I, Agave BioSystems proposes to develop novel catalytically active oligonucleotides against G-nerve agents using high throughput selection in E. coli. The development of a high-throughput selection method in E. coli to identify novel RNA molecules able to hydrolyze nerve agents constitutes a promising and innovative approach. Unlike other methods typically used for the de novo creation of new RNA or DNA catalysts, this in vivo approach will directly identify molecules combining favorable binding and dissociation constants, as well as strong catalytic activity.